Breast Cancer Clinical Trial
Official title:
A Phase II Trial of Preoperative HER2 Targeting and Endocrine Therapy in Postmenopausal Women With HER2 and HR Positive Breast Cancer
The purpose of this study is to evaluate whether trastuzumab and letrozole are effective and safe in the preoperative treatment for postmenopausal patients with hormone receptor-positive and HER2-positive breast cancer.
Eligibility criteria
- Ages Eligible for Study: ≥ 20 years
- Invasive cancer (clinical stage IB-IIIB)
- Measurable tumor larger than 1cm
- ECOG status 0 or 1
- Postmenopausal women
- Age ≥55 years and amenorrhea
- Age <55 years and amenorrhea for ≥12 months with FSH >30 mIU/ml
- HER2 positive tumor
- 3 positive on IHC
- 2 positive on IHC with HER2 gene amplification on FISH or SISH using a single-probe
or dual-probe
- Estrogen receptor positive tumor
- Positive ER expression with Allred score more than PS3/TS8 or modified Allred score
more than PS4/TS7
- Eligible cardiac function
- Normal heard evaluated by ECG
- Consider clinically non-significant arrythmia and ischemic change as normal
- LVEF ≥ 55% measured by ECHO or MUGA scan
Outcome measures
- Primary End-point
- The rate of pathologic complete response (pCR)
- No residual invasive cancer in breast
- Secondary End-point
- Clinical Response Rate
- Safety profiles for the preoperative use of concurrent trastuzumab and letrozole
- The rate of breast conservative surgery
- Total pathologic complete response (tpCR)
- No residual invasive cancer in breast and ipsilateral axilla
- Analysis of biomarkers based on baseline specimen and residual tumor
- Ki67 expression
- cDNA microarray: gene expression profiling
- Association between clinical response rate and circulating tumor cells (CTCs)
- CTCs are measured by CytoGen (SEOUL, KOREA)"
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |